This research uses a validated rodent model of psychosis to study sensory-filtering deficits linked to schizophrenia. Instead of blocking dopamine D2 receptors, the study uses CDPPB to modulate mGlu5 receptors and reduce D2 hypersensitivity. Treatment restores normal sensory gating, suggesting a promising therapeutic pathway with fewer side effects than current antipsychotics.